Quantification of HER family receptors in breast cancer

摘要: The clinical success of trastuzumab in breast cancer taught us that appropriate tumor evaluation is mandatory for the correct identification patients eligible targeted therapies. Although HER2 protein expression by immunohistochemistry (IHC) and gene amplification fluorescence situ hybridization (FISH) assays are routinely used to select receive trastuzumab, both only partially predict response drug. In case epidermal growth factor receptor (EGFR), link between presence or its anti-EGFR therapies could not be demonstrated. Even less known HER3 HER4, mainly due lack robust validated detecting these proteins. It becoming evident that, besides FISH IHC, we need better quantify HER receptors categorize individualized treatments. Here, present current available methodologies measure family discuss implications target quantification.